← Back to Search

Growth Hormone Secretagogue Receptor Agonist

Anamorelin for Pancreatic Cancer

Phase 2
Recruiting
Research Sponsored by Lahey Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 25 weeks

Summary

This trial is testing a new drug to see if it's effective and safe for people with a certain type of cancer.

Who is the study for?
Adults over 18 with advanced pancreatic cancer and cachexia (weight loss and muscle wasting), who have not had major surgery recently, are not pregnant or breastfeeding, do not have other severe health issues like heart failure or uncontrolled diabetes, and can take pills. They must be willing to follow the study rules and use reliable contraception if necessary.
What is being tested?
The trial is testing Anamorelin HCl against a placebo in people with advanced pancreatic cancer. Participants will randomly receive either the drug or a placebo once daily before their first meal for 25 weeks to see if it helps improve appetite and weight.
What are the potential side effects?
Specific side effects of Anamorelin HCl aren't listed here, but common ones may include nausea, fatigue, increased blood sugar levels, and potential heart-related issues due to its intended effects on appetite and metabolism.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~25 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 25 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Weight change
Secondary study objectives
AEs
Anorexia Questionnaire
Fatigue Questionnaire
+3 more
Other study objectives
Chemotherapy Dose change
Unplanned visits

Side effects data

From 2023 Phase 3 trial • 318 Patients • NCT03743051
9%
Non-small cell lung cancer
9%
Anaemia
6%
Nausea
5%
Asthenia
4%
Hyperkalaemia
4%
Fatigue
4%
Dyspnoea
4%
Oedema Peripheral
3%
Decreased Appetite
3%
Platelet Count Decreased
3%
Hypocalcaemia
3%
Leukopenia
3%
Headache
3%
Diarrhoea
2%
Vomiting
2%
Metastases to central nervous system
1%
Back pain
1%
Depressed level of consciousness
1%
Chemical peritonitis
1%
Pain
1%
Sepsis
1%
Intracranial pressure increased
1%
Arthralgia
1%
Intestinal obstruction
1%
Osteonecrosis of jaw
1%
Oesophageal stenosis
1%
Autoimmune colitis
1%
Urinary bladder haemorrhage
1%
Viral infection
1%
Atrial flutter
1%
Acute respiratory failure
1%
Pulmonary embolism
1%
Respiratory failure
1%
Bronchitis
1%
Peritonitis
1%
Pneumonia
1%
Pericardial effusion
1%
Acute myocardial effusion
1%
Cardiac arrest
1%
Cardiac failure
1%
Myocardial infarction
1%
Gastric haemorrhage
1%
Ileus
1%
Small intestinal ulcer perforation
1%
Chronic obstructive pulmonary disease
1%
Hypoxia
1%
Cerebrovascular accident
1%
Haematuria
1%
Hydronephrosis
1%
Pancytopenia
1%
Pyrexia
1%
Thrombocytopenia
1%
Chest Pain
1%
Neutropenia
100%
80%
60%
40%
20%
0%
Study treatment Arm
100 mg Anamorelin HCl
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: AnamorelinExperimental Treatment1 Intervention
Patients randomized to anamorelin HCL will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
Group II: PlaceboPlacebo Group1 Intervention
Patients randomized to placebo will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Anamorelin Hydrochloride
2019
Completed Phase 3
~350

Find a Location

Who is running the clinical trial?

Lahey ClinicLead Sponsor
72 Previous Clinical Trials
244,958 Total Patients Enrolled
Helsinn Healthcare SAIndustry Sponsor
41 Previous Clinical Trials
9,361 Total Patients Enrolled
Quartesian LLCUNKNOWN

Media Library

Anamorelin Hydrochloride (Growth Hormone Secretagogue Receptor Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT04844970 — Phase 2
Pancreatic Cancer Research Study Groups: Anamorelin, Placebo
Pancreatic Cancer Clinical Trial 2023: Anamorelin Hydrochloride Highlights & Side Effects. Trial Name: NCT04844970 — Phase 2
Anamorelin Hydrochloride (Growth Hormone Secretagogue Receptor Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04844970 — Phase 2
~37 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top